ArticleCytoJournal2024
Investigating the role of exosomal microRNA-5703 in modulating tumor-associated endothelial cells in lung cancer.
Article in CytoJournal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.Discover oncology · 2026Review
- JAK/STAT3 axis in breast cancer: opportunities for intervention with natural phytochemical-based nanotherapeutics.Medical oncology (Northwood, London, England) · 2026Review
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.International journal of nanomedicine · 2026Review
- Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression.International journal of molecular sciences · 2025Review
- Targeting cancer via macrophage-derived exosomal miRNAs: implications for tumor progression and resistance.Frontiers in immunology · 2025Review
- Cadherin family genes in non-small cell lung cancer: implications for diagnosis, prognosis, and targeted therapy.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Lung cancer, as a prevalent malignancy, continues to be a considerable clinical challenge. This study aimed to elucidate the role of microRNA-5703 (miR-5703) in lung cancer progression and to assess the effect of exosomal miR-5703 on tumor-associated endothelial cells (TAECs). Material and Methods: We analyzed Gene Expression Omnibus datasets and performed quantitative real-time polymerase chain reaction to determine miR-5703 expression levels in lung cancer tissues. Exosomes derived from lung cancer cells were identified, and the effects of miR-5703 inhibitors or mimics on malignant biological behavior were evaluated in the lung cancer cells. Moreover, to understand these effects on TAECs, we assessed angiogenesis, endothelial-mesenchymal transition (EndMT), and barrier function after treatment with miR- 5703 inhibitors or the exosome-assimilated inhibitor cytochalasin D. Tumor-bearing mouse models were used in validating the tumor-promoting effects of exosomes derived from lung cancer cells, and the markers of angiogenesis, EndMT, and barrier function were examined. Results: Our results showed that miR-5703 was up-regulated in the lung cancer cells and patient-derived exosomes. miR-5703 facilitated cell growth, migration, invasion, in LC cells, and impaired the barrier function, which promoted angiogenesis and EndMT of TAECs by carrying in exosomes through targeting inhibitor of growth family member 4 (ING4) was identified as target of miR-5703 ( Conclusion: miR-5703 operates as an oncogenic factor in lung cancer. After being taken up by TAECs, exosomal miR-5703 promotes angiogenesis, EndMT, and barrier damage by targeting ING4. Hence, miR-5703 is a potential target in the lung cancer microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.